THACI, D.; GORDON , K. .; GOODERHAM, M.; STROBER , B.; KORMAN, N.; BANERJEE, S.; BANERJEE, S.; COLSTON, E.; KIM, J.; THROUP, J.; MORITA, A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s37, 2021. DOI: 10.25251/skin.5.supp.37. Disponível em: Acesso em: 12 aug. 2022.